pI: 6.2361 |
Length (AA): 327 |
MW (Da): 36961 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | Bloodstream Form. | Siegel TN |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | Procyclic. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_130980)
Species | Accession | Gene Product |
---|---|---|
Brugia malayi | Bm1_35010 | MHCK/EF2 kinase domain family protein |
Caenorhabditis elegans | CELE_F42A10.4 | Protein EFK-1, isoform B |
Dictyostelium discoideum | DDB_G0292150 | Alpha kinase family protein |
Echinococcus granulosus | EgrG_000237000 | eukaryotic elongation factor 2 kinase |
Echinococcus multilocularis | EmuJ_000237000 | eukaryotic elongation factor 2 kinase |
Homo sapiens | 101930123 | eukaryotic elongation factor 2 kinase-like |
Homo sapiens | ENSG00000103319 | eukaryotic elongation factor 2 kinase |
Leishmania braziliensis | LbrM.35.4800 | myosin heavy chain kinase a-like protein |
Leishmania donovani | LdBPK_364780.1 | myosin heavy chain kinase a-like protein |
Leishmania infantum | LinJ.36.4780 | myosin heavy chain kinase a-like protein |
Leishmania major | LmjF.36.4700 | myosin heavy chain kinase a-like protein |
Leishmania mexicana | LmxM.36.4551 | myosin heavy chain kinase a-like protein |
Loa Loa (eye worm) | LOAG_04841 | hypothetical protein |
Mus musculus | ENSMUSG00000035064 | eukaryotic elongation factor-2 kinase |
Schistosoma japonicum | Sjp_0128290 | Elongation factor 2 kinase, putative |
Schistosoma japonicum | Sjp_0087030 | ko:K08292 elongation factor 2 kinase [EC2.7.11.20], putative |
Schistosoma japonicum | Sjp_0309020 | expressed protein |
Schistosoma mansoni | Smp_072980 | eukaryotic elongation factor 2 kinase (eef-2 kinase) |
Schmidtea mediterranea | mk4.006866.00 | Eukaryotic elongation factor 2 kinase |
Schmidtea mediterranea | mk4.001647.04 | |
Schmidtea mediterranea | mk4.011939.00 | Mucolipin, putative |
Schmidtea mediterranea | mk4.000429.02 | |
Schmidtea mediterranea | mk4.001647.02 | Mucolipin, putative |
Schmidtea mediterranea | mk4.000429.04 | |
Schmidtea mediterranea | mk4.006866.01 | Eukaryotic elongation factor 2 kinase |
Schmidtea mediterranea | mk4.001647.05 | |
Trypanosoma brucei gambiense | Tbg972.8.7690 | myosin heavy chain kinase A, putative |
Trypanosoma brucei gambiense | Tbg972.4.5150 | myosin heavy chain kinase A, putative |
Trypanosoma brucei | Tb927.8.7450 | myosin heavy chain kinase A, putative |
Trypanosoma brucei | Tb927.4.4970 | myosin heavy chain kinase A, putative |
Trypanosoma congolense | TcIL3000_8_7840 | myosin heavy chain kinase A, putative |
Trypanosoma congolense | TcIL3000_8_7690 | myosin heavy chain kinase A, putative |
Trypanosoma congolense | TcIL3000_4_4190 | myosin heavy chain kinase A, putative |
Trypanosoma cruzi | TcCLB.510681.20 | myosin heavy chain kinase A, putative |
Trypanosoma cruzi | TcCLB.509011.100 | myosin heavy chain kinase A, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.8.7450 this record | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb927.8.7450 this record | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.8.7450 this record | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb927.8.7450 this record | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
Tb927.4.4970 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.4.4970 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.4.4970 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb927.4.4970 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | decreased (PATO:0000468) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | decreased (PATO:0000468) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Homo sapiens | eukaryotic elongation factor 2 kinase-like | Compounds | References |
1 literature reference was collected for this gene.